GlassScriptPhysician profile
Earl Vendryes Campbell
NPI 1841566650
$5,162.08
in general payments reported to CMS, 2019-2025
22 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.40 · 2020: $11.07 · 2021: $391 · 2022: $418 · 2023: $479 · 2024: $1,918 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443 · Travel and Lodging: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.96 |
| Travel and Lodging | $1,800.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,317.47 | 2019-2025 | Exalt Model D, Axios, Apollo Esg System |
| Ovesco Endoscopy USA, INC. | $881.17 | 2024 | |
| Ferring Pharmaceuticals INC. | $400.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $264.01 | 2021 | |
| Abbvie INC. | $222.04 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.04 | 2024 | Xifaxan |
| Olympus America INC. | $171.80 | 2023-2025 | Visiglide, Endoclot Air Compressor, Gastrointestinal Videoscope |
| 3-D Matrix, INC. | $74.20 | 2024 | |
| Conmed Corporation | $57.97 | 2025 | Conmed Biliary |
| Exact Sciences Corporation | $57.85 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $57.81 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $48.89 | 2024 | Entyvio |
| Janssen Biotech, INC. | $43.04 | 2024 | Stelara, Tremfya |
| Genzyme Corporation | $36.86 | 2024 | |
| Lilly USA, LLC | $33.08 | 2024 | Omvoh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.22 | 2024 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $28.18 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $23.60 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $22.57 | 2025 | Terlivaz |
| Tepha INC | $22.46 | 2019 | |
| Merck Sharp & Dohme LLC | $18.16 | 2022 | |
| Novo Nordisk INC | $14.06 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.